Dr. Skerrett is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
525 E 68th St
# 69
New York, NY 10065Phone+1 646-253-2808Fax+1 212-746-3856
Education & Training
Columbia UniversityMSC, Public Health-BioStatistics, 2001 - 2003
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1987 - 1989
Baylor College of MedicineResidency, Internal Medicine, 1984 - 1987
Lewis Katz School of Medicine at Temple UniversityClass of 1984- University of PennsylvaniaBA, Biology, 1975 - 1979
Certifications & Licensure
NY State Medical License 1988 - 2026
NJ State Medical License 2003 - 2009- American Board of Internal Medicine Internal Medicine
- American Board of Pathology Blood Banking/Transfusion Medicine
Clinical Trials
- Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF) Start of enrollment: 2007 Oct 01
- Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction Start of enrollment: 2008 Mar 01
- Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar Fusion Start of enrollment: 2008 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 5 citationsThe significance of a positive DAT in thalassemia patients.Suzanne A. Arinsburg, Donna Skerrett, Dorothy A. Kleinert, Patricia J. Giardina, Melissa M. Cushing
Immunohematology. 2020-01-01 - 40 citationsSafety, tolerability, clinical, and joint structural outcomes of a single intra-articular injection of allogeneic mesenchymal precursor cells in patients following ant...Yuanyuan Wang, Andrew Shimmin, Peter Ghosh, Paul Marks, James M. Linklater
Arthritis Research & Therapy. 2017-08-02 - 144 citationsA Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure.Emerson C. Perin, Kenneth M. Borow, Guilherme V. Silva, Anthony N. DeMaria, Oscar C. Marroquin
Circulation Research. 2015-08-28
Press Mentions
Paradigm Achieves Primary Endpoint in PARA_OA_008 Synovial Fluid Biomarker Phase 2 Clinical TrialOctober 6th, 2022- Paradigm Doses First Subjects in Phase III Knee Osteoarthritis TrialMay 5th, 2022
- First Subjects Randomized and Dosed in the U.S. Under Phase III Pivotal Trial for the Treatment of Pain Associated with Knee OAMay 4th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
